1.Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. 2004 The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 44(4):398-404
2.Hemmelgarn BR, McAllister FA, Myers MG, et al. 2005 The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1-blood pressure measurement, diagnosis, and assessment of risk. Can J Cardiol 21:645-656
3.Vasan RS, Evans JC, Larson MG, et al. 2004 Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351:33-41
4.Gordon RD, Stowasser M, Tunny TJ, et al. 1994 High incidence of primary hyperaldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21:315-318
5.Fardella CE, Mosso L, Gomez-Sanchez CE, et al. 2000 Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85:1863-1867
6.Mulatero P, Milan A, Fallo F, et al. 2006 Comparison of confirmatory tests for the diagnosis of primary aldosteronism. J Clin Endocrinol Metab 91(7):2618-23
7.Williams JS, Williams GH, Raji A, et al. 2006 Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalemia. J Hum Hypertens 20:129-136
8.Stowasser M, Gordon RD. 2000 Primary aldosteronism: learning from the study of familial varieties. J Hypertension 18:1165-1176
9.Streeten DH, Tomycz N, Anderson GH. 1979 Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 67:403-413
10.Seiler L, Rump LC, Schulte-Monting J, et al. 2004 Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 150:329-337
11.Mattson C, Young WF Jr. 2006 Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2:198-208
12.Giacchetti G, Ronconi V, Lucarelli G, et al. 2006 Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 24:737-745
13.Ulick S, Blumenfeld JD, Atlas SA, et al. 1992 The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. J Clin Endocrinol Metab 76:873-878
14.Thompson GB, Young WF Jr. 2006 Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. World J Surg 886-887
15.Young WF, Stanson AW, Thompson GB, et al. 2004 Role of adrenal venous sampling in primary aldosteronism. Surgery 136:1227-1235
16.Toniato A, Bernante P, Rossi GP, Pelizzo MR. 2006 The role of adrenal venous sampling in the surgical management of primary aldosteronism. World J Surg 30:624-627
17.Gordon RD, Stowasser M. 1998 Familial forms broaden the horizons for primary aldosteronism. Trends Endocrinol Metab 9:220-223
18. Stowasser M, Gordon RD. 2006 Monogenic mineralocorticoid hypertension. Best Pract Res Clin Endocrinol Metab 20:401-420
19.Sutherland DJ, Ruse JL, Laidlaw JC. 1966 Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 95:1109-1119
20.Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. 1992 A chimeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262-265
21.Litchfield WR, Anderson BF, Weiss RJ, et al. 1998 Intracranial aneurysms and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31:445-450
22.Litchfield WR, New MI, Coolidge C, et al. 1997 Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 82:3570-3573
23.Grim CE, Weinberger MH. 1980 Familial, dexamethasone-suppressible, normokalemic hyperaldosteronism. Pediatrics 65:597-604
24.Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD, Stratakis CA. 2000 A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7p22. J Med Genet 37:831-835
25.Stowasser M, Gordon RD. 2006 Aldosterone assays: an urgent need for improvement. Clin Chem 52:1640-1642
26.Schirpenbach C, Seiler L, Maser-Gluth C, et al. 2006 Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassay with and without extraction steps. Clin Chem 52:1749-1755
27.Kratzsch J, Hahnel D, Koch CA. Salt suppression test in individuals from age 20 to 65 (German dissertation, Hahnel D)
28.Weinberger MH, Fineberg NS. 1993 The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Int Med 153:2125-2129
29.Young WF. 2002 Primary aldosteronism. Ann NY Acad Sci 970:61-76
30.Meyer A, Brabant G, Behrend M. 2005 Long-term follow-up after adrenalectomy for primary aldosteronism. World J Surg 29:155-159
31.Rossi GP. 2006 Surgically correctable hypertension caused by primary aldosteronism. Best Pract Res Clin Endocrinol Metab 20:385-400
32.Magni P, Motta M. 2005 Aldosterone receptor antagonists: biology and novel therapeutic applications. Curr Hypertens Rep 7:206-211
33.Gordon RD, Laragh JH, Funder JW. 2005 Low renin hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol Metab 16:108-113
34.Karagiannis A, Tziomalos K, Kakafika A, et al. 2006 Eplerenone relieves spironolactone-induced painful gynecomastia in a patient with primary aldosteronism. Nephrol Dial Transplant Oct
35.Catena C, Lapenna R, Baroselli S, et al. 2006 Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91:3457-3463
36.Koch CA, Vortmeyer AO, Zhuang Z, Brouwers FM, Pacak K. 2002 New insights into the genetics of familial chromaffin cell tumors. Ann NY Acad Sci 970:11-28
37.Neumann HPH, et al. 2002 Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1486-1488
38.Koch CA, Pacak K, Chrousos GP. 2002 The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 87(12):5367-84
39.Lenders JW, Eisenhofer G, Mannelli M, Pacak K. 2005 Phaeochromocytoma. Lancet 366:665-675
40.Reisch N, Peczkowska M, Januszewicz A, Neumann HPH. 2006 Pheochromocytoma: presentation, diagnosis, and treatment. J Hypertens 24:2331-2339
41.Eisenhofer G, Walther MM, Huynh TT, et al. 2001 Pheochromoytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86:1999-2008
42.Agarwal A, Gupta S, Mishra AK, et al. 2005 Normotensive pheochromocytoma: institutional experience. World J Surg 29:1185-1188
43.Bravo EL, Tagle R. 2003 Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24:539-553
44.Lenders JW, Pacak K, Walther MM, et al. 2002 Biochemical diagnosis of pheochromocytoma: which test is best ? JAMA 287:1427-1434
45.Unger N, Pitt C, Schmidt IL, et al. 2006 Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 154:409-417
46.Miehle K, Kratzsch J, Lenders JW, Kluge R, Paschke R, Koch CA. 2005 Adrenal incidentaloma diagnosed as pheochromocytoma by plasma chromogranin A and plasma metanephrines. J Endocrinol Invest 28:1040-1042
47.Grossrubatscher E, Dalino P, Vignati F, et al. 2006 The role of chromogranin A in the management of patients with pheochromocytoma. Clin Endocrinol 65:287-293
48.Giovanella L, Squin N, Ghelfo A, Ceriani L. 2006 Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. Q J Nucl Med Mol Imaging 50:344-347
49.Koch CA, Rodbard JS, Brouwers FM, Eisenhofer G, Pacak K. 2003 Hypotension in a woman with a metastatic dopamine-secreting carotid body tumor. Endocr Pract 9:310-314
50.Zachmann M, Tassinari D, Prader A. 1983 Clinical and biochemical variabilitiy of congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. J Endocrinol Metab 56:222-229
51.New MI, Geller DS, Fallo F, Wilson RC. 2005 Monogenic low rennin hypertension. Trends Endocrinol Metab 16:92-97
52.Wong SL, Shu SG, Tsai CR. 2006 Seventeen alpha-hydroxylase deficiency. J Formos Med Assoc 105:177-181
53.Costa-Santos M, Kater CE, Auchus RJ, et al. 2004 Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab 89:49-60
54.Lavery GG, Ronconi V, Draper N, et al. 2003 Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 42:123-129
55.Carvajal CA, Gonzales AA, Romero DG, Gonzales A, et al. 2003 Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 88:2501-2507
56.Palermo M, Quinkler M, Stewart PM. 2004 Apparent mineralocorticoid excess syndrome: an overview. Arq Bras Endocrinol Metab 48:687-696
57.Lin-Su K, Zhou P, Arora N, et al. 2004 In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess. J Clin Endocrinol Metab 89:2024-2027
58.New MI, Levine LS, Biglieri EG, Paeira J, Ulick S. 1977 Evidence for an unidentified ACTH-induced steroid hormone causing hypertension. J Clin Endocrinol Metab 44:924-933
59.Wilson RC, Krozowski ZS, Li K, et al. 1995 A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80:2263-2266
60.Stewart PM, Corrie JE, Shackleton CH, Edwards CR. 1988 Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 82:340-349
61.Arriza JL, Weinberger C, Cerelli G, Glaser TM, et al. 1987 Cloning of the human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275
62.Funder JW, Pearce PT, Smith R, Smith AI. 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor mediated. Science 242:583-585
63.Heilmann P, Buchheim E, Wacker J, Ziegler R. 2001 Alteration of the activity of the 11beta-hydroxysteroid dehydrogenase in pregnancy: relevance for the development of pregnancy-induced hypertension ? J Clin Endocrinol Metab 276:5222-5226
64.Quinkler M, Oelkers W, Diederich S. 2000 In vivo measurement of renal 11beta-hydroxysteroid dehydrogenase type 2 activity. J Clin Endocrinol Metab 85:4921-4922
65.Geller DS, Farhi A, Pinkerton N, et al. 2000 Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289:119-123
66.Liddle GW, Bledsoe T, Coppage WS Jr. 1963 A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 76:199-213
67.Gordon RD, Geddes RA, Pawsey CG, O’Halloran MW. 1970 Hypertension and severe hyperkalemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 19:287-294
68.Geller DS. 2005 Mineralocorticoid resistance. Clin Endocrinol 62:513-520
69.Klemm SA, Gordon RD, Tunny TJ, Thompson RE 1991 The syndrome of hypertension and hyperkalemia with normal GFR (Gordon’s syndrome): is there increased proximal sodium reabsorption ? Clin Invest Med 14:551-558
70.Wilson FH, Disse-Nicodeme S, Choate KA, et al. 2001 Human hypertension caused by mutations in WNK kinases. Science 293:11-14
71.Mansfield TA, Simon DB, Farfel Z, et al. 1997 Multilocus linkage of familial hyperkalemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p-q21. Nat Genet 16:202-205
72.Kahle KT, Wilson FH, Leng Q, et al. 2003 WNK4 regulates the balance between renal NaCl reabsorption and K secretion. Nat Genet 35:372-376
73.Xie J, Craig L, Cobb MH, Huang CL. 2006 Role of with-no-lysine (K) kinases in the pathogenesis of Gordon’s syndrome. Pediatr Nephrol 21(9):1231-6
74.Tobin MD, Raleigh SM, Newhouse S, et al. 2005 Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. Circulation 112:3423-3429
75.Wofford MR, King DS, Harrel TK. 2006 Drug-induced metabolic syndrome. J Clin Hypertens 8:114-119
76.Haffner SM, Ruilope L, Dahlof B, et al. 2006 Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. J Cardiovasc Pharmacol 47:469-475
77.Saad MF, Rewers M, Selby J, et al. Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension 43:1324-1331
78.Ferrannini E, Buzzigoli G, Bonadonna R, et al. 1987 Insulin resistance in essential hypertension. N Engl J Med 317:350-357
79.Wofford MR, Hall JE. 2004 Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 10:3621-3637
80.Levy J, Gavin JR III, Hammermann MR, et al. 1986 Ca- and Mg-ATPase activity in kidney basolateral membrane in non insulin dependent diabetic rats: effect of insulin. Diabetes 35:899-905
81.Dluhy RG, Lawrence JE, Williams GH. Endocrine Hypertension. In: Williams Textbook of Endocrinology, 10th edition, Saunders, 2002, pages 552-585
82.Ronti T, Lupattelli G, Mannarino E. 2006 The endocrine function of adipose tissue:an update. Clin Endocrinol 64:355-365
83.Bukoski RD, Ishibashi K, Bian K. 1995 Vascular actions of the calcium regulating hormones. Semin Nephrol 15:536-549
84.Bucher HC, Cook RJ, Guyatt GH, et al. 1996 Effects of dietary calcium supplementation in blood pressure: a metaanalysis of randomized controlled trials. JAMA 275:1016-1022
85.Allender PS, Cutler JA, Follmann D, et al. 1996 Dietary calcium and blood pressure: a metaanalysis of randomized clinical trials. Ann Intern Med 124:825-831
86.Silverberg SJ. 2002 Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res Supp;2:N117-25
87.Rubin MR, Maurer MS, McMahon DJ, et al. 2005 Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab 90:3326-3330
88.Savage M, Lienhardt A, Lebrethon M, et al. 2001 Cushing’s disease in childhood : presentation, investigation, treatment and long-term outcome. Horm Res 55:24-30
89.Magiakou M, Mastorakos G, Oldfield EH, et al. 1994 Cushing’s syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 331:629-636
90.Zacharieva S, Orbetzova M, Stoynev A, et al. 2004 Circadian blood pressure profile in patients with Cushing’s syndrome before and after treatment. J Endocrinol Invest 27:924-930
91.Baid S, Nieman LK. 2004 Glucocorticoid excess and hypertension. Curr Hypertens Rep 6:493-499
92.Torpy DJ, Mullen N, Ilias I, Nieman LK. 2002 Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion. Ann NY Acad Sci 970:134-144
93.Mantero F, Boscaro M. 1992 Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol 43:409-413
94.Pirpiris M, Yeung S, Dewar E, et al. 1993 Hydrocortisone-induced hypertension in men. The role of cardiac output. Am J Hypertension 6:287-294
95.Newell-Price J, Bertagna X, Grossman AB, Nieman LK. 2006 Cushing’s syndrome. Lancet 367:1605-1617
96.Kino T, Vottero A, Charmandari E, Chrousos GP. 2002 Familial/sporadic glucocorticoid resistance syndrome and hypertension. Ann NY Acad Sci 970:101-111
97.Chrousos GP, Vingerhoeds A, Brandon D, et al. 1982 Primary cortisol resistance. J Clin Invest 69:1261-1269
98.Danzi S, Klein I. 2003 Thyroid hormone and blood pressure regulation. Curr Hypertens Rep 5:513-520
99.Prisant LM, Gujral JS, Mulloy AL. 2006 Hyperthyroidism: a secondary cause of isolated systolic hypertension. J Clin Hypertens 8:596-599
100.Klein I. 1990 Thyroid hormone and the cardiovascular system. Am J Med 88:631-637
101.Woeber KA. 1992 Thyrotoxicosis and the heart. N Engl J Med 327:94-98
102.Tamer I, Sargin M, Sargin H, et al. 2005 The evaluation of left ventricular hypertrophy in hypertensive patients with subclinical hyperthyroidism. Endocr J 52:421-425
103.Volzke H, Alte D, Dorr M, et al. 2006 The association between subclinical hyperthyroidism and blood pressure in a population-based study. J Hypertens 24:1947-1953
104.Biondi B, Klein I. 2004 Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 24:1-13
105.Streeten DHP, Anderson GH Jr, Howland T, et al. 1988 Effects of thyroid function on blood pressure: recognition of hypothyroid hypertension. Hypertension 11:78-83
106.Iqbal A, Figenschau Y, Jorde R. 2006 Blood pressure in relation to serum thyrotropin : the Tromso study. J Hum Hypertens
107.Walsh JP, Bremner AP, Bulsara MK, et al. 2006 Subclinical thyroid dysfunction and blood pressure: a community-based study. Clin Endocrinol 65:486-491
108.Vitale G, Pivonello R, Auriemma RS, et al. 2005 Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol 63:470-476
109.Bondanelli M, Amrosio MR, Degliuberti EC. 2001 Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 4:239-249
110.Colao A, Ferone D, Marzullo P, et al. 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152
111.Falkheden T, Sjögren B. 1964 Extracellular fluid volume and renal function in pituitary insufficiency and acromegaly. Acta Endocrinol 46:80-88
112.Lombardi G, Galdiero M, Auriemma RS, et al. 2006 Acromegaly and the cardiovascular system. Neuroendocrinology 83:211-217
113.Mulatero P, Veglio F, Maffei P, et al. 2006 CYP11B2-344T/C gene polymorphism and blood pressure in patients with acromegaly. J Clin Endocrinol Metab Sept